Biogen wins FDA approval for high-dose Spinraza

The U.S. Food and Drug Administration (FDA) has approved a high-dose formulation of Biogen Inc.'s drug, Spinraza, used to treat a rare muscle disorder. This approval provides Biogen with a competitive advantage against Novartis AG's gene therapy. The enhanced dosage offers a new treatment option for patients and strengthens Biogen's position in the rare disease market.